Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus for intermediate-grade FDG-avid pancreatic neuroendocrine tumors
ACTRN12612001252808Phase 2Recruiting
- Sponsor
- Peter MacCallum Cancer Centre
- Start
- Dec 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of everolimus in islet cell tumor, sponsored by Peter MacCallum Cancer Centre. Primary endpoint: Progression-free survival at 6 months. Started Dec 2012; status: recruiting.
02
Drugs
everolimus
03
Conditions
islet cell tumor
Beyond the preview
Go deeper on ACTRN12612001252808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12612001252808.